Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease. As a result, following its expected launch in 2012, Dimebon will garner peak year sales of $1.5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Phase III CONTACT clinical trial for patients with moderate-to-severe Alzheimer's disease will investigate the effect of Dimebon on neuropsychiatric symptoms and activities of daily living in patients who are already receiving a stable dose of donepezil (Eisai/Pfizer's Aricept, Bracco's Memac). The Phase III CONSTELLATION clinical trial will investigate slightly different end points: the effect of Dimebon on cognition, memory and activities of daily living in patients already receiving a stable dose of memantine (Merz/Grupo Grunenthal's Axura/Akatinol, Lundbeck's Ebixa, Forest Laboratories' Namenda).

The Pharmacor finding from the topic entitled Alzheimer's Disease also reveals that, through 2018, robust 11 percent annual growth in the Alzheimer's disease drug market will be driven by the launch and uptake of new anti-amyloid monoclonal antibodies, most notably Johnson & Johnson/Pfizer's bapineuzumab and Eli Lilly's solanezumab.

"Although monoclonal antibodies are expected to offer superior efficacy over other drugs in the market, their uptake will be initially slow following their launches, owing to potential safety concerns," said Decision Resources Analyst Matthew Winton, Ph.D. "Nevertheless, bapineuzumab and solanezumab will achieve combined sales of nearly $6 billion in 2018."

About Pharmacor

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.     For more information, contact:     Decision Resources       Decision Resources, Inc.   Christopher Comfort      Elizabeth Marshall   781-296-2597             781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,; or Elizabeth Marshall of Decision Resources, Inc.,

A Hypertension Drug Requiring Less-Frequent Dosing Than Novartis's Diovan/Tareg Would Earn Similar Patient Share in Europe and U.S.

View Now